Extended Data Fig. 10: Conserved function of LILRBs in M-MDSC activation.
From: Secretogranin 2 binds LILRB4 resulting in immunosuppression
a, Proportions of myeloid cell subsets (monocytes, macrophages, DCs, and mast cells) across eight tumor types, analyzed from publicly available single-cell RNA-seq datasets. b, Bubble heatmap showing expression of selected signature genes across myeloid subsets. Dot size represents the percentage of cells expressing each gene; colored intensity indicates normalized average expression levels. c, Co-IP of Flag-tagged LILRB1-5 and STAT3 in the presence or absence of Lyn in HEK293T cells. HEK293T cells were co-transfected with Flag- LILRB1-5 (2 μg), Lyn (500 ng), and STAT3 (2 μg) plasmids. After 48 h, lysates were subjected to IP with anti-Flag beads and immunoblotting. d, Co-IP analysis of STAT3 binding to Flag-tagged LILRB1, LILRB4, or achimeric receptor combining the ECD of LILRB1 and ICD of LILRB4 (ECDLILRB1-ICDLILRB4), co-transfected in HEK293T cells. After 48 h, lysates were subjected to IP with anti-Flag beads and immunoblotting. e-f, Immunoblot (e) and quantification (f) of p-STAT3, p-SHP1, and p-SHP2 in human CD14+ monocytes from healthy donors stimulated with or without IL-6 (20 ng/mL) for 10 min in 96-well plates coated with BSA or indicated antibodies (n = 3 biological replicates). Data are presented as mean ± s.d. p values were determined by one-way ANOVA with Tukey’s multiple comparisons test.
